UK: Stretching Intellectual Property to Maximise Royalties

Last Updated: 20 December 2002
Article by Janita Good

The life sciences sector has long embraced the use of licensing throughout the drug discovery pipeline, from the in-licensing of promising new compounds to eventual out-licensing of manufacture of the approved product. With increasingly diverse techniques now employed in the drug discovery process, licensing specific technologies and expertise is becoming ever more popular. For instance, a biotech company concentrating on innovation and research might also out-license access to its library of lead compounds relating to a particular target. This provides revenue for the biotech company for development of its own compounds, and establishes the relationship with Big Pharma for potential out-licensing deals in the future.

Some commentators believe the industry’s love affair with licensing is set to become even more intense. Recent consolidation e.g. the merger of Pfizer and Pharmacia, they say, will inevitably lead to those products with smaller potential markets being out-licensed for development to smaller companies. Such merger activity could mark a new wave of consolidation towards ever-larger companies, increasingly dependant on blockbuster products, whether home–grown or in-licensed. Combined with the need to encourage innovation, particularly in the early stages of drug discovery, Big Pharma is becoming increasingly reliant on licensing deals with biotech to supplement its ailing product pipeline.

Given the increasing use of licensing IP in the life sciences sector, in this article we outline, from a licensor’s perspective, some of the key strategies to consider in maximising long-term revenue generation. In the life science industry IP licences typically exploit patents and know-how associated with the patent. Other rights, however, such as registered trade marks, copyright and database rights should not be over looked. Each IP right is governed by different legal rules and all but trade marks expire after a specified period. In this sector the limited life of a patent is particularly restrictive. However, knowledge of the differences between each IP right coupled with skilful licence drafting can effectively stretch the licensor’s revenue.

Generally in the UK patent protection cannot be extended beyond 20 years from the date the patent application was filed. This creates the obvious problem for patents relating to a drug which may take up to 10 years to obtain market authorisation. Patent legislation recognises this problem but only to a very limited extent. The patent may be extended by a formula which takes the number of years between these two dates and reduces it by 5 years, subject to a cap of 5 years. This is the UK equivalent of the US "Hatch-Waxman Act".

Once patented, proprietary technology is often transferred using a patent and know how license. "Know how", at least in this context, is confidential information which is disclosed to the licensor for the exclusive purpose of allowing the licensee to work and fully utilise the patent. In theory, all the information required to work a patent should be contained within the "enabling disclosure" required for the patent to be granted. However, as anybody who has ever attempted to repeat an experiment from published methodology will be aware, often essential steps are omitted. The same is true of patents – without the requisite know how a patent might not be fully exploitable or, in some cases, might be completely worthless. Disclosure and licensing of know-how is therefore crucial for licensees. But can a know-how licence also be used to effectively generate a royalty stream beyond the life of the patent? Further, there is the risk that during the term of the license the patent may be challenged and revoked causing monopoly protection to be lost, as in Eli Lilly’s loss of its patent on Prozac. In these situations separate licences for different IP rights could help preserve at least some of the Licensor’s royalties.

If two separate licences are entered in to, thus clearly distinguishing the royalty for the patent and the royalty for the associated know-how, it may be possible to enjoy the royalty for the know-how after the patent licence has expired. However, because know how is not, at least strictly speaking, a proprietary IP right, great care must be taken in considering the strict duties of confidentiality to be placed upon the licensee and the remedies available in the event such obligations are breached.

Furthermore, if some of the know-how can be embodied within a database, the extraction of the data from the database can be licensed as proprietary IP. Database rights are time limited but if the database is regularly updated or extended the duration clock can be effectively restarted. This relatively new UK IP right could therefore in certain circumstances last for ever.

In a similar way, the licensee could be granted a licence to use the licensor’s registered trade mark to promote sales of the patented product. During the life of the patent, a successfully branded product might be expected to capture a significant market share, and when the drug goes "off patent" the branded version will inevitably continue to enjoy a premium over its generic rivals. In these circumstances the licensor can continue to command a royalty in return for the licensee’s use of its trade mark.

Care must be taken however when considering these techniques because any measures which have the effect (intentionally or otherwise) of increasing the duration for which royalties would be payable in return for rights to exploit patents and/or know-how may be anti-competitive unless they can be brought within the Technology Transfer Block Exemption. The consequences of entering in to an anti-competitive licensing agreement, which does not fall within the Technology Transfer Block Exemption, can be both serious and expensive, with fines imposed on the offending entity of up to 10% of worldwide turnover.

In an arena where licensing is key for providing revenue for biotech companies in a difficult fund raising market and where Big Pharma is looking to the biotech sector for innovation through in-licensing at much earlier stages in the drug discovery process, the structure and terms of licenses have increasing importance. Dissecting out different IP rights to be separately licensed can be a powerful mechanism for stretching the life of the rights and so generate additional royalties.

The content of this article does not constitute legal advice and should not be relied on in that way. Specific advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions